Ranitidine and the probable human carcinogen N-nitrosodimethylamine (NDMA)

Ranitidine, sold under the trade name Zantac among others, is a medication which decreases stomach acid production. It is commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. There is also tentative evidence of benefit for hives. Wikipedia

Molar mass: 314.404 g/mol

Formula: C₁₃H₂₂N₄O₃S

Onset of action: 55–65 minutes (150 mg dose); 55–115 minutes (75 mg dose)

Trade name: Zantac, others

Excretion: 30–70% Kidney

Elimination half-life: 2–3 hours

People also search for: Omeprazole, Famotidine, Pantoprazole, MORE

FDA recalls ranitidine medicines over potential cancer causing impurity
BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l5832 (Published 02 October 2019)
Cite this as: BMJ 2019;367:l5832
Article
Related content
Metrics
Responses
Elisabeth Mahase
Author affiliations
The US Food and Drug Administration has asked doctors and patients to return certain batches of over-the-counter ranitidine tablets (75 mg and 150 mg), after low levels of the probable human carcinogen N-nitrosodimethylamine (NDMA) were detected.1

The FDA released updates to the public and doctors explaining that some ranitidine medicines might contain low levels of NDMA and asked for any tablets labelled by Walgreens, Walmart, or Rite-Aid …